There is now significant evidence to support an independent causal role for lipoprotein
(a)(Lp (a)) as a risk factor for atherosclerotic cardiovascular disease. Plasma Lp (a) …

Background and aims Lipoprotein (a)[Lp (a)] and interleuking-6 (IL-6), an inflammation
biomarker, have been established as distinct targets of the residual atherosclerotic …

Lipoprotein (a)[Lp (a)], is present only in humans, Old World nonhuman primates, and the
European hedgehog. Lp (a) has many properties in common with low-density lipoprotein …

Lipoprotein (a) Lp (a) is a cholesterol‐rich, LDL‐like particle that is independently
associated with an increased risk for ischemic heart disease, atherosclerosis, thrombosis …

Objective: Lp (a)(lipoprotein [a]) concentrations are associated with atherosclerotic
cardiovascular disease (ASCVD), and new therapies that enable potent and specific …

High levels of lipoprotein (a)[Lp (a)], an apoB100-containing lipoprotein, are an independent
and causal risk factor for atherosclerotic cardiovascular diseases through mechanisms …

Abstract Lipoprotein (a)[Lp (a)] is an established cardiovascular risk factor, and growing
evidence indicates its causal association with atherosclerotic disease because of the …

Growing evidence has shown that high levels of lipoprotein (a)(Lp (a)) and chronic
inflammation may be responsible for the residual risk of cardiovascular events in patients …

Recent published studies have provided increasing evidence that lipoprotein (a)[Lp (a)] may
be a potential causal, genetic, independent risk factor for cardiovascular disease (CVD). Lp …

Purpose of Review A considerable body of data from genetic and epidemiological studies
strongly support a causal relationship between high lipoprotein (a)[Lp (a)] levels, and the …